Files

826090.pdf (753.46 KB)

Document type

Article

Version

Accepted version

Publication date

2023-08-14

Publication license

cc-by-nc-nd (c) Elsevier B.V., 2023
Please use this identifier to cite or link to this item: https://hdl.handle.net/2445/218975

Cost-utility analysis of the use of the 20-valent anti-pneumococcal vaccine (PCV20) in adults older than 60 years in Spain

Journal Title

Authors

Director/Tutor

Journal ISSN

Volume Title

Related resource

https://doi.org/10.1016/j.vaccine.2023.07.016

Abstract

A cost-utility analysis was conducted to assess the efficiency of implementing a PCV20 vaccination strategy in the Spanish adult population older than 60 years, for the prevention of non-bacteremic pneumococcal pneumonia (NBP) and invasive pneumococcal disease (IPD).

Subject

Vacuna antipneumocòccica, Anàlisi cost-benefici

Subject (English)

Pneumococcal vaccine, Cost effectiveness

Citation

Collections

Articles publicats en revistes (Genètica, Microbiologia i Estadística)

Citation

CANTARERO, David, et al. Cost-utility analysis of the use of the 20-valent anti-pneumococcal vaccine (PCV20) in adults older than 60 years in Spain. Vaccine. 2023. Vol. 41, num. 36, pags. 5342-5349. ISSN 0264-410X. [consulted: 18 of June of 2026]. Available at: https://hdl.handle.net/2445/218975

Export metadata

JSON - METS

Share record